Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation
Status:
Active, not recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
This research study is a Phase II clinical trial, which tests the safety and effectiveness of
an investigational drug to learn whether the drug works in treating a specific cancer.
"Investigational" means that the drug is still being studied. It also means that the FDA has
not yet approved afatinib for use in patients.
In this research study the investigators are looking to see if taking afatinib after surgery
works better when taken over a short period of time, compared to a long period of time.